JP2009509920A5 - - Google Patents

Download PDF

Info

Publication number
JP2009509920A5
JP2009509920A5 JP2008525976A JP2008525976A JP2009509920A5 JP 2009509920 A5 JP2009509920 A5 JP 2009509920A5 JP 2008525976 A JP2008525976 A JP 2008525976A JP 2008525976 A JP2008525976 A JP 2008525976A JP 2009509920 A5 JP2009509920 A5 JP 2009509920A5
Authority
JP
Japan
Prior art keywords
disorder
pain
post
psychiatric disorders
neurological
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008525976A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009509920A (ja
JP5031745B2 (ja
Filing date
Publication date
Priority claimed from PCT/US2005/028760 external-priority patent/WO2006020879A1/fr
Application filed filed Critical
Priority claimed from PCT/US2006/005246 external-priority patent/WO2007021308A1/fr
Publication of JP2009509920A publication Critical patent/JP2009509920A/ja
Publication of JP2009509920A5 publication Critical patent/JP2009509920A5/ja
Application granted granted Critical
Publication of JP5031745B2 publication Critical patent/JP5031745B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008525976A 2005-08-12 2006-02-15 代謝型グルタミン酸受容体増強性イソインドロン Expired - Fee Related JP5031745B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US2005/028760 WO2006020879A1 (fr) 2004-08-13 2005-08-12 Composes a base d'isoindolone et leur utilisation comme potentialisateurs du recepteur metabotropique du glutamate
USPCT/US2005/028760 2005-08-12
PCT/US2006/005246 WO2007021308A1 (fr) 2005-08-12 2006-02-15 Isoindolones potentiateurs du récepteur glutamate métabotropique

Publications (3)

Publication Number Publication Date
JP2009509920A JP2009509920A (ja) 2009-03-12
JP2009509920A5 true JP2009509920A5 (fr) 2009-04-23
JP5031745B2 JP5031745B2 (ja) 2012-09-26

Family

ID=36464390

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008525976A Expired - Fee Related JP5031745B2 (ja) 2005-08-12 2006-02-15 代謝型グルタミン酸受容体増強性イソインドロン
JP2008525977A Pending JP2009509921A (ja) 2005-08-12 2006-02-15 置換イソインドロン類及び代謝調節型グルタミン酸受容体増強剤としてのその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008525977A Pending JP2009509921A (ja) 2005-08-12 2006-02-15 置換イソインドロン類及び代謝調節型グルタミン酸受容体増強剤としてのその使用

Country Status (4)

Country Link
EP (2) EP1912940A1 (fr)
JP (2) JP5031745B2 (fr)
CN (2) CN101277934A (fr)
WO (2) WO2007021308A1 (fr)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807706B2 (en) 2005-08-12 2010-10-05 Astrazeneca Ab Metabotropic glutamate-receptor-potentiating isoindolones
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
US20080139846A1 (en) * 2006-09-01 2008-06-12 Astrazeneca Ab New Process 298
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
WO2008130853A1 (fr) * 2007-04-17 2008-10-30 Astrazeneca Ab Hydrazides et leur utilisation en tant que potentialisateurs des récepteurs métabotropiques du glutamate
US20100197800A1 (en) * 2007-04-23 2010-08-05 Richard Friedman Treatment and/or Prevention of Presbycusis by Modulation of Metabotropic Glutamate Receptor 7
EP2167464B1 (fr) 2007-05-25 2014-12-03 AbbVie Deutschland GmbH & Co KG Composés hétérocycliques comme modulateurs positifs du récepteur métabotropique du glutamate 2 (récepteur mglu2)
TWI417100B (zh) * 2007-06-07 2013-12-01 Astrazeneca Ab 二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途
TW200911255A (en) 2007-06-07 2009-03-16 Astrazeneca Ab Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841
WO2009004430A1 (fr) * 2007-06-29 2009-01-08 Pfizer Inc. N-benzyl oxazolidinones et composés hétérocycliques apparentés comme potentialisateurs de récepteurs du glutamate
KR20100080597A (ko) 2007-09-14 2010-07-09 오르토-맥닐-얀센 파마슈티칼스 인코포레이티드 １,３-이치환된-４-페닐-1ｈ-피리딘-2-온
US9114138B2 (en) 2007-09-14 2015-08-25 Janssen Pharmaceuticals, Inc. 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′] bipyridinyl-2′-ones
SA109300358B1 (ar) * 2008-06-06 2012-11-03 استرازينيكا ايه بي مقويات مستقبل جلوتامات ذي انتحاء أيضي من أيزو إندولون
GB0811643D0 (en) 2008-06-25 2008-07-30 Cancer Rec Tech Ltd New therapeutic agents
TW201006801A (en) 2008-07-18 2010-02-16 Lilly Co Eli Imidazole carboxamides
RU2510396C2 (ru) 2008-09-02 2014-03-27 Янссен Фармасьютикалз, Инк. 3-азабицикло[3.1.0]гексильные производные в качестве модуляторов метаботропных глутаматных рецепторов
US8697689B2 (en) 2008-10-16 2014-04-15 Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
BRPI0921333A2 (pt) 2008-11-28 2015-12-29 Addex Pharmaceuticals Sa derivados de indol e benzoxazina como moduladores de receptores de glutamato metabotrópicos
WO2010104195A1 (fr) * 2009-03-11 2010-09-16 Banyu Pharmaceutical Co.,Ltd. Nouveau dérivé d'isoindolin-1-one
SG176021A1 (en) 2009-05-12 2011-12-29 Janssen Pharmaceuticals Inc 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
NZ596053A (en) 2009-05-12 2013-05-31 Janssen Pharmaceuticals Inc 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
ES2451350T3 (es) * 2009-10-09 2014-03-26 Celgene Corporation Procedimientos para la preparación de compuestos de 2-(1-feniletil)isoindolin-1-ona
WO2011051490A2 (fr) 2009-11-02 2011-05-05 N.V. Organon Dérivés hétérocycliques
BR112012016786A2 (pt) * 2010-01-07 2015-09-01 Astrazeneca Ab Processos para preparar 7-metil-5-(3-piperazin-1-ilmetil-[1,2,4]oxadiazol-5-il)-2-(4- trifluorometoxibenzil)-2
US8664214B2 (en) 2010-03-30 2014-03-04 AbbVie Deutschland GmbH & Co. KG Small molecule potentiators of metabotropic glutamate receptors I
US8314120B2 (en) 2010-03-30 2012-11-20 Abbott Gmbh & Co. Kg Small molecule potentiators of metabotropic glutamate receptors
PT2649069E (pt) 2010-11-08 2015-11-20 Janssen Pharmaceuticals Inc Derivados de 1,2,4-triazolo[4,3-a]piridina e sua utilização como moduladores alostéricos positivos de recetores mglur2
US9012448B2 (en) 2010-11-08 2015-04-21 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
EP2661435B1 (fr) 2010-11-08 2015-08-19 Janssen Pharmaceuticals, Inc. Dérivés 1,2,4-triazolo[4,3-a]pyridine et leur utilisation en tant que modulateurs allostériques positifs des récepteurs mglur2
WO2013056015A1 (fr) 2011-10-14 2013-04-18 Incyte Corporation Dérivés d'isoindolinone et de pyrrolopyridinone en tant qu'inhibiteurs d'akt
EP2770997B1 (fr) * 2011-10-28 2016-09-14 Vanderbilt University Analogues substitues 2-(4-heterocyclylbenzyle)isoindoline-1-un employes comme modulateurs allosteriques positifs du recepteur m1 acetylcholine muscarinique
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
SI3431106T1 (sl) 2014-01-21 2021-03-31 Janssen Pharmaceutica Nv Kombinacije, ki vsebujejo pozitivne alosterične modulatorje metabotropnega glutamatergičnega receptorja podtipa 2 in njihova uporaba
DK3096790T3 (da) 2014-01-21 2019-10-07 Janssen Pharmaceutica Nv Kombinationer omfattende positive allosteriske modulatorer eller orthosteriske agonister af metabotrop glutamaterg subtype 2-receptor og anvendelse af disse
TWI713455B (zh) 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法
GB201517216D0 (en) 2015-09-29 2015-11-11 Cancer Res Technology Ltd And Astex Therapeutics Ltd Pharmaceutical compounds
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
BR112018008711A2 (pt) 2015-10-29 2018-10-30 Effector Therapeutics Inc compostos de pirrolo-, pirazolo-, imidazo-pirimidina e piridina que inibem mnk1 e mnk2
AU2016343687A1 (en) 2015-10-29 2018-06-07 Effector Therapeutics, Inc. Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of Mnk1 and Mnk2
US10000487B2 (en) 2015-11-20 2018-06-19 Effector Therapeutics, Inc. Heterocyclic compounds that inhibit the kinase activity of Mnk useful for treating various cancers
CN105837557A (zh) * 2016-05-05 2016-08-10 青岛辰达生物科技有限公司 一种用于治疗ii型糖尿病的阿格列汀的制备方法
CN106279182B (zh) * 2016-07-29 2019-06-07 中国药科大学 一种吡咯并[2，1-a]异吲哚酮类化合物及其合成方法
SG11201907356SA (en) 2017-02-14 2019-09-27 Effector Therapeutics Inc Piperidine-substituted mnk inhibitors and methods related thereto
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
EP3459939A1 (fr) * 2017-09-26 2019-03-27 Pragma Therapeutics Nouveaux composés hétérocycliques comme modulateurs de mglur7
KR20210102211A (ko) 2018-10-24 2021-08-19 이펙터 테라퓨틱스, 인크. Mnk 억제제의 결정질 형태
WO2020102216A1 (fr) 2018-11-13 2020-05-22 Incyte Corporation Dérivés hétécycliques substitués utiles en tant qu'inhibiteurs de pi3k
US11161838B2 (en) 2018-11-13 2021-11-02 Incyte Corporation Heterocyclic derivatives as PI3K inhibitors
US11078204B2 (en) 2018-11-13 2021-08-03 Incyte Corporation Heterocyclic derivatives as PI3K inhibitors
CN110498759A (zh) * 2019-09-12 2019-11-26 天津瑞岭化工有限公司 异吲哚啉酮类化合物的合成方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE620654C (de) * 1933-04-29 1935-10-24 Smith & Sons Ltd S Geschwindigkeitsanzeiger
US3579524A (en) * 1968-06-05 1971-05-18 Miles Lab 2-aminoalkyl derivatives of phthalimidines
US3993617A (en) * 1975-10-30 1976-11-23 Morton-Norwich Products, Inc. Antifungal 2-substituted phthalimidines
DE3717561A1 (de) * 1987-05-25 1988-12-08 Thomae Gmbh Dr K Indol-, isochinolin- und benzazepinderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
JPH02184667A (ja) * 1989-01-11 1990-07-19 Meiji Seika Kaisha Ltd Ｎ，ｎ’―ジ置換ピペラジル誘導体及びそれを有効成分とする排尿障害改善剤
TW219935B (fr) * 1991-12-25 1994-02-01 Mitsubishi Chemicals Co Ltd
US5681954A (en) * 1993-05-14 1997-10-28 Daiichi Pharmaceutical Co., Ltd. Piperazine derivatives
RU2124511C1 (ru) * 1993-05-14 1999-01-10 Фармасьютикал Ко., Лтд Производные пиперазина
JP2001524468A (ja) * 1997-11-21 2001-12-04 エヌピーエス ファーマシューティカルズ インコーポレーテッド 中枢神経系疾患を治療するための代謝調節型グルタミン酸受容体アンタゴニスト
DE60129210T2 (de) * 2000-02-29 2008-03-20 Mitsubishi Pharma Corp. Zyklische amid-derivate
DE10031391A1 (de) * 2000-07-03 2002-02-07 Knoll Ag Bicyclische Verbindungen und ihre Verwendung zur Prophylaxe und Therapie der zerebralen Ischämie
JP5079202B2 (ja) * 2000-07-18 2012-11-21 大日本住友製薬株式会社 セロトニン再取り込み阻害剤
DE10238865A1 (de) * 2002-08-24 2004-03-11 Boehringer Ingelheim International Gmbh Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
GB0223232D0 (en) * 2002-10-07 2002-11-13 Pfizer Ltd Chemical compounds
WO2005040157A2 (fr) * 2003-10-22 2005-05-06 Eli Lilly And Company Nouveaux antagonistes des recepteurs de l'hormone mch
US20080275062A1 (en) * 2004-01-30 2008-11-06 David Harold Drewry Chemical Compounds
AU2005219791B2 (en) * 2004-03-05 2011-06-09 Msd K.K. Diaryl-substituted five-membered heterocycle derivative
DK1731512T3 (en) * 2004-03-05 2015-01-05 Nissan Chemical Ind Ltd Isoxazoline-substituted benzamide AND INSTRUMENTS FOR COMBATING HARMFUL ORGANISMS
TW200613272A (en) * 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators

Similar Documents

Publication Publication Date Title
JP2009509920A5 (fr)
JP2009509921A5 (fr)
RU2009147708A (ru) Производные оксадиазола и их применение в качестве потенцирующих средств метаботропных глутаматных рецепторов-842
JP2012530129A5 (fr)
MY148002A (en) (2s,3r)-n-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms, and methods of use thereof
WO2009117515A8 (fr) Nouveaux composés servant à traiter les maladies et troubles du système nerveux central
JP2013544277A5 (fr)
MX2010001824A (es) Heterociclos como moduladores de canal de potasio.
MX2016008842A (es) Derivados de n-fenil-lactama capaces de estimular la neurogenesis y su uso en el tratamiento de trastornos neurologicos.
HRP20140867T1 (hr) Heterocikliäśki sulfonamidi, njihova upotreba i farmaceutski pripravci
MY154877A (en) 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamateric synaptic responses
GB2462235A (en) NMDA and MC receptor antagonists exhibiting neuroprotective and memory enhancing activities
JP2008519056A5 (fr)
JP2014500885A5 (fr)
TN2009000278A1 (en) 3-substituted-[1,2,3] benzotriazinone compounds for enhancing glutamatergic synaptic responses
MX2010009643A (es) Derivados de 2-aminoquinolina como antagonistas del receptor 5-hidroxitriptamina (5a).
MX362532B (es) Derivados de 1,7-naftiridina.
JP2016506939A5 (fr)
WO2014017936A3 (fr) Composés d'urée et leur utilisation en tant qu'inhibiteurs d'enzyme
WO2009001356A3 (fr) Dérivés de l'acyl-urée et utilisations
JP2017502069A5 (fr)
BRPI0508124A (pt) 2-piridinil[7-(piridin-4-il)pirazolo[1,5-a]piridimidin-3-il] metanonas
JP2010523540A5 (fr)
RU2016132574A (ru) Органические соединения
ZA200903652B (en) Methods for treating disruptive behavior disorders